338 related articles for article (PubMed ID: 34552244)
1. Biologically informed deep neural network for prostate cancer discovery.
Elmarakeby HA; Hwang J; Arafeh R; Crowdis J; Gang S; Liu D; AlDubayan SH; Salari K; Kregel S; Richter C; Arnoff TE; Park J; Hahn WC; Van Allen EM
Nature; 2021 Oct; 598(7880):348-352. PubMed ID: 34552244
[TBL] [Abstract][Full Text] [Related]
2. Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies.
Snow O; Lallous N; Ester M; Cherkasov A
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823970
[TBL] [Abstract][Full Text] [Related]
3. [Molecular pathology of prostate cancer].
Tímár J
Magy Onkol; 2019 Mar; 63(1):5-9. PubMed ID: 30889615
[TBL] [Abstract][Full Text] [Related]
4. Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway.
Maruyama Y; Miyazaki T; Ikeda K; Okumura T; Sato W; Horie-Inoue K; Okamoto K; Takeda S; Inoue S
PLoS One; 2014; 9(10):e108743. PubMed ID: 25285958
[TBL] [Abstract][Full Text] [Related]
5. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
[TBL] [Abstract][Full Text] [Related]
6. UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.
Gao Y; Liu Y; Liu Y; Peng Y; Yuan B; Fu Y; Qi X; Zhu Q; Cao T; Zhang S; Yin L; Li X
Cancer Lett; 2021 Nov; 520():172-183. PubMed ID: 34265399
[TBL] [Abstract][Full Text] [Related]
7. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific Antigen Response and Eradication of Androgen Receptor Amplification with High-dose Testosterone in Prostate Cancer.
Schiff JP; Lewis BE; Ledet EM; Sartor O
Eur Urol; 2017 Jun; 71(6):997-998. PubMed ID: 28040353
[No Abstract] [Full Text] [Related]
9. Knowledge-primed neural networks enable biologically interpretable deep learning on single-cell sequencing data.
Fortelny N; Bock C
Genome Biol; 2020 Aug; 21(1):190. PubMed ID: 32746932
[TBL] [Abstract][Full Text] [Related]
10. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.
Sun T; Lee GS; Oh WK; Pomerantz M; Yang M; Xie W; Freedman ML; Kantoff PW
Clin Cancer Res; 2010 Nov; 16(21):5244-51. PubMed ID: 20855462
[TBL] [Abstract][Full Text] [Related]
11. The Path of Most Resistance: Transdifferentiation Underlies Exceptional Nonresponses to Androgen Receptor Pathway Inhibition in Prostate Cancer.
Sinha S; Nelson PS
Cancer Discov; 2017 Jul; 7(7):673-674. PubMed ID: 28684411
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor plasticity and its implications for prostate cancer therapy.
Snow O; Lallous N; Singh K; Lack N; Rennie P; Cherkasov A
Cancer Treat Rev; 2019 Dec; 81():101871. PubMed ID: 31698174
[TBL] [Abstract][Full Text] [Related]
13. Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer.
Armstrong K; Ahmad I; Kalna G; Tan SS; Edwards J; Robson CN; Leung HY
Br J Cancer; 2011 Oct; 105(9):1362-9. PubMed ID: 21952621
[TBL] [Abstract][Full Text] [Related]
14. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
15. Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.
He Y; Johnson DT; Yang JS; Wu H; You S; Yoon J; Lee DH; Kim WK; Aldahl J; Le V; Hooker E; Yu EJ; Geradts J; Cardiff RD; Sun Z
Oncogene; 2019 Sep; 38(38):6507-6520. PubMed ID: 31358900
[TBL] [Abstract][Full Text] [Related]
16. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
[TBL] [Abstract][Full Text] [Related]
17. The role of tumor suppressor dysregulation in prostate cancer progression.
Dean JL; Knudsen KE
Curr Drug Targets; 2013 Apr; 14(4):460-71. PubMed ID: 23410128
[TBL] [Abstract][Full Text] [Related]
18. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
19. [Molecular genetic mechanisms of drug resistance in prostate cancer].
Krasnov GS; Dmitriev AA; Sadritdinova AF; Volchenko NN; Slavnova EN; Danilova TV; Snezhkina AV; Melnikova NV; Fedorova MS; Lakunina VA; Belova AA; Nyushko KM; Alekseev BY; Kaprin AD; Kudryavtseva AV
Mol Biol (Mosk); 2015; 49(5):716-27. PubMed ID: 26510590
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer.
Koivisto P; Visakorpi T; Kallioniemi OP
Scand J Clin Lab Invest Suppl; 1996; 226():57-63. PubMed ID: 8981668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
